Investigators reported results of a Phase III trial to evaluate the efficacy of omidubicel compared to standard umbilical cord blood transplantation.
[Blood]
6445218
{6445218:XQVHJVIF}
apa
50
1
163789
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-035ae35a7246eb02f18d1a6be9513faf%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XQVHJVIF%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Horwitz%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHorwitz%2C%20M.%20E.%2C%20Stiff%2C%20P.%20J.%2C%20Cutler%2C%20C.%20S.%2C%20Brunstein%2C%20C.%20G.%2C%20Hanna%2C%20R.%2C%20Maziarz%2C%20R.%20T.%2C%20Rezvani%2C%20A.%20R.%2C%20Karras%2C%20N.%20A.%2C%20McGuirk%2C%20J.%20P.%2C%20Valcarcel%2C%20D.%2C%20Schiller%2C%20G.%20J.%2C%20Lindemans%2C%20C.%20A.%2C%20Hwang%2C%20W.%20Y.%2C%20Koh%2C%20L.-P.%2C%20Keating%2C%20A.%20K.%2C%20Khaled%2C%20Y.%2C%20Hamerschlak%2C%20N.%2C%20Frankfurt%2C%20O.%2C%20Peled%2C%20T.%2C%20%26%23x2026%3B%20Sanz%2C%20G.%20F.%20%282021%29.%20Omidubicel%20Versus%20Standard%20Myeloablative%20Umbilical%20Cord%20Blood%20Transplantation%3A%20Results%20of%20a%20Phase%20III%20Randomized%20Study.%20%3Ci%3EBlood%3C%5C%2Fi%3E%2C%20%3Ci%3Eblood.2021011719%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2021011719%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2021011719%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DXQVHJVIF%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Omidubicel%20Versus%20Standard%20Myeloablative%20Umbilical%20Cord%20Blood%20Transplantation%3A%20Results%20of%20a%20Phase%20III%20Randomized%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%20E%22%2C%22lastName%22%3A%22Horwitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20Joseph%22%2C%22lastName%22%3A%22Stiff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corey%20S%22%2C%22lastName%22%3A%22Cutler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20G%22%2C%22lastName%22%3A%22Brunstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rabi%22%2C%22lastName%22%3A%22Hanna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20T.%22%2C%22lastName%22%3A%22Maziarz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20R.%22%2C%22lastName%22%3A%22Rezvani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%20Amalia%22%2C%22lastName%22%3A%22Karras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20P%22%2C%22lastName%22%3A%22McGuirk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Valcarcel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%20John%22%2C%22lastName%22%3A%22Schiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%20A.%22%2C%22lastName%22%3A%22Lindemans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20YK%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liang-Piu%22%2C%22lastName%22%3A%22Koh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20K%22%2C%22lastName%22%3A%22Keating%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasser%22%2C%22lastName%22%3A%22Khaled%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelson%22%2C%22lastName%22%3A%22Hamerschlak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Frankfurt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Peled%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irit%22%2C%22lastName%22%3A%22Segalovich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beth%22%2C%22lastName%22%3A%22Blackwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Wease%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%20S%22%2C%22lastName%22%3A%22Freedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Einat%22%2C%22lastName%22%3A%22Galamidi-Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillermo%20F.%22%2C%22lastName%22%3A%22Sanz%22%7D%5D%2C%22abstractNote%22%3A%22Omidubicel%20is%20an%20ex%20vivo%20expanded%20hematopoietic%20progenitor%20cell%2C%20and%20non-expanded%20myeloid%20and%20lymphoid%20cell%20product%20derived%20from%20a%20single%20umbilical%20cord%20blood%20unit.%20We%20report%20results%20of%20a%20phase%20III%20trial%20to%20evaluate%20the%20efficacy%20of%20omidubicel%20compared%20to%20standard%20umbilical%20cord%20blood%20transplantation%20%28UCBT%29.%20Between%20January%202017%20and%20January%202020%2C%20125%20patients%20aged%2013-65%20with%20hematologic%20malignancies%20were%20randomized%20to%20omidubicel%20versus%20standard%20UCBT.%20Patients%20received%20myeloablative%20conditioning%20and%20graft%20versus%20host%20disease%20%28GvHD%29%20prophylaxis%20with%20a%20calcineurin%20inhibitor%20and%20mycophenolate%20mofetil.%20The%20primary%20endpoint%20was%20time%20to%20neutrophil%20engraftment.%20The%20treatment%20arms%20were%20well%20balanced%20and%20racially%20diverse.%20Median%20time%20to%20neutrophil%20engraftment%20was%2012%20days%20%2895%25%20CI%2010-14%20days%29%20and%2022%20days%20%2895%25%20CI%2019-25%20days%29%20%28p%26lt%3B0.001%29%20for%20the%20omidubicel%20and%20control%20arms%2C%20respectively.%20The%20cumulative%20incidence%20of%20neutrophil%20engraftment%20was%2096%25%20and%2089%25%20for%20patients%20receiving%20omidubicel%20and%20control%20transplants%2C%20respectively.%20The%20omidubicel%20arm%20had%20faster%20platelet%20recovery%20%2855%25%20vs.%2035%25%20recovery%20by%2042%20days%2C%20p%3D0.028%29%2C%20a%20lower%20incidence%20of%20first%20grade%202%5C%2F3%20bacterial%20or%20invasive%20fungal%20infections%20%2837%25%20vs.%2057%25%2C%20p%3D0.027%29%2C%20and%20spent%20more%20time%20out%20of%20hospital%20during%20the%20first%20100%20days%20following%20transplant%20%28median%2061%20vs.%2048%20days%2C%20p%3D0.005%29%20than%20controls.%20Differences%20in%20GvHD%20and%20survival%20between%20the%20two%20arms%20were%20not%20statistically%20significant.%20Transplantation%20with%20omidubicel%20results%20in%20faster%20hematopoietic%20recovery%20and%20reduced%20early%20transplant-related%20complications%20as%20compared%20to%20standard%20UCBT.%20The%20results%20suggest%20that%20omidubicel%20may%20be%20considered%20as%20a%20new%20standard%20of%20care%20for%20adult%20patients%20eligible%20for%20UCBT.%22%2C%22date%22%3A%22June%2022%2C%202021%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2021011719%22%2C%22ISSN%22%3A%220006-4971%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2021011719%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-23T18%3A11%3A35Z%22%7D%7D%5D%7D
Horwitz, M. E., Stiff, P. J., Cutler, C. S., Brunstein, C. G., Hanna, R., Maziarz, R. T., Rezvani, A. R., Karras, N. A., McGuirk, J. P., Valcarcel, D., Schiller, G. J., Lindemans, C. A., Hwang, W. Y., Koh, L.-P., Keating, A. K., Khaled, Y., Hamerschlak, N., Frankfurt, O., Peled, T., … Sanz, G. F. (2021). Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study. Blood, blood.2021011719. https://doi.org/10.1182/blood.2021011719 Cite